These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3452529)

  • 1. [Treatment of 63 advanced ovarian carcinomas].
    Liu LY; Hong WJ; Hou YJ; Yao ZH; Wu AR; Li L
    Zhonghua Zhong Liu Za Zhi; 1987 Sep; 9(5):375-8. PubMed ID: 3452529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
    Li M; Huang X
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer.
    Feng Y; Sun T
    Chin Med J (Engl); 1998 Aug; 111(8):722-5. PubMed ID: 11245027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies of second-look operations (SLO) in ovarian cancer].
    Yuzawa H
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for advanced ovarian cancer.
    Schwartz PE; Chambers JT; Makuch R
    Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
    Hainsworth JD; Malcolm A; Johnson DH; Burnett LS; Jones HW; Greco FA
    Obstet Gynecol; 1983 May; 61(5):619-23. PubMed ID: 6403897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
    Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
    Huang X; Cai SM; Tang J; Li ZT; Zang RY
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of ovarian cancer in the Southern Swedish Health Care Region during the five-year period 1974-1978.
    Sigurdsson K; Johnsson JE; Möller T
    Ann Chir Gynaecol; 1983; 72(5):260-7. PubMed ID: 6318647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma.
    Sun T; Feng Y; Zhu Y; Zheng Y
    Chin Med J (Engl); 2000 Jul; 113(7):625-7. PubMed ID: 11776033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance of clinically prognostic factors in the treatment of advanced ovarian carcinoma].
    Albrecht M; Goepel E; Simon WE; Trams G
    Geburtshilfe Frauenheilkd; 1985 Jul; 45(7):482-7. PubMed ID: 2993094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of ovarian endodermal sinus tumor.
    Lian L; Huang H; Huang R; Lang J
    Chin Med J (Engl); 1996 May; 109(5):344-8. PubMed ID: 9208488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
    Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
    J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
    Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
    Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.
    Piver S; Barlow JJ; Chung WS; Lee FT; Vongtama V
    Natl Cancer Inst Monogr; 1975 Oct; 42():177-82. PubMed ID: 825780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy in the management of ovarian germ cell malignancies.
    Schwartz PE
    Obstet Gynecol; 1984 Oct; 64(4):564-72. PubMed ID: 6207473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.